3,5-二溴-D-酪氨酸 | 50299-42-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 酪氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3,5-二溴-D-酪氨酸
• 英文名称: (R)-3,5-bromotyrosine bromate
• 英文别名: D-3,5-dibromotyrosine；3,5-dibromo-D-tyrosine；3,5-Dibrom-D-tyrosin；(2R)-2-azaniumyl-3-(3,5-dibromo-4-hydroxyphenyl)propanoate
• CAS: 50299-42-8
• 化学式: C₉H₉Br₂NO₃
• 分子量: 338.983
• InChiKey: COESHZUDRKCEPA-SSDOTTSWSA-N

物化性质

• 沸点：
  416.6±45.0 °C(Predicted)
• 密度：
  2.014±0.06 g/cm3(Predicted)
• 熔点：
  245.0 °C
• 溶解度：
  0.01 M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储于室温环境。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,5-Dibromo-D-tyrosine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,5-Dibromo-D-tyrosine
CAS number: 50299-42-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9Br2NO3
Molecular weight: 339.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3,5-二溴-D-酪氨酸是一种酪氨酸衍生物。

反应信息

• 作为反应物：
  描述：

  3,5-二溴-D-酪氨酸 在 碳酸氢钠 、 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.5h， 生成 (R)-2-((tert-butoxycarbonyl)amino)-3-(3,5-dibromo-4-methoxyphenyl)propionic acid
  参考文献：
  名称：

  一种溴代酪氨酸生物碱类化合物及其制备方 法和用途

  摘要：

  本发明属于医药技术领域，具体涉及一种溴代酪氨酸生物碱类化合物及其制备方法和用途。本发明首次提供了通式Ⅰ和通式Ⅱ所示的溴代酪氨酸生物碱类化合物及其制备方法，以及在制备抗肿瘤药物中的应用。该溴代酪氨酸生物碱类化合物抗肿瘤活性好，制备方法简单可行，收率较好，具有广阔的应用前景。

  公开号：

  CN107739316B
• 作为产物：
  描述：

  3-sulfo-L-tyrosine 在 氢溴酸 、 溴 作用下， 生成 3,5-二溴-D-酪氨酸
  参考文献：
  名称：

  Kaneko, Nippon Kagaku Kaishi/Journal of the Chemical Society of Japan, 1938, vol. 59, p. 433,438

  摘要：

  DOI：

文献信息

• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CGRP
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2017072721A1

  公开（公告）日：2017-05-04

  The disclosures herein relate to novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本公开涉及公式（I）中的新化合物，其中R1、R2、R3和R4如本文所定义，并且它们在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。
• Bioactive peptides
  申请人：ALPHARMA AS

  公开号：US20030022821A1

  公开（公告）日：2003-01-30

  The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.

  本发明提供一种改性乳铁蛋白肽，其具有细胞毒性，长度为7至25个氨基酸，含有三个或更多阳离子残基，并且与天然乳铁蛋白序列相比，具有一个或多个额外的笨重和亲脂氨基酸，以及其酯、酰胺、盐和环状衍生物，以及制备这些肽的方法、含有这些肽的药物组合物和将这些肽用作药物的用途，特别是作为抗菌或抗肿瘤剂。
• Antimicrobial compounds and formulations
  申请人：——

  公开号：US20030195144A1

  公开（公告）日：2003-10-16

  The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

  本发明涉及使用分子制造药物，该分子包括长度为2至35个非氢原子的骨架，至少连接有两个笨重和亲脂性基团，并且具有至少一个阳离子多于阴离子的基团，用作破坏微生物细胞膜的药物，并且涉及使用包括长度为2至35个非氢原子的骨架的分子，该分子共价连接有一个超级笨重和亲脂性基团，包括至少9个非氢原子，并且具有至少两个阳离子多于阴离子的基团，作为膜作用抗微生物药物的用途，以及涉及此类分子的治疗方法，特别是包括肽衍生物和肽类似物的肽。
• Inhibition of tumour growth
  申请人：Eliassen Tone Liv

  公开号：US20080019993A1

  公开（公告）日：2008-01-24

  The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoural agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumour growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.

  本发明提供了一种细胞毒性的7至25个氨基酸残基的肽，其中含有三个或更多阳离子残基，其中含有一个或多个非遗传性的臃肿和亲脂性氨基酸，以及它们的酯类、酰胺、盐和环状衍生物，以及制备这些肽的方法、含有它们的药物组合物以及它们作为药物的用途，特别是作为抗菌或抗肿瘤剂。在一个优选方面，本发明提供了利用所述肽在主体中诱导适应性免疫反应以抑制肿瘤生长或建立的方法，以及利用其他溶解剂在主体中诱导适应性免疫反应的方法。
• Antimicrobial Compounds and Formulations
  申请人：Svendsen John Sigurd

  公开号：US20120108520A1

  公开（公告）日：2012-05-03

  The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

  本发明涉及使用一种分子，其包含长度为2至35个非氢原子的骨架，并且至少连接有两个笨重和亲脂性基团，并且具有至少一个阳离子大于阴离子的基团，在制造破坏微生物细胞膜的药物方面使用该分子。另外，本发明还涉及使用一种分子作为膜作用抗微生物剂，该分子包括长度为2至35个非氢原子的骨架，并且共价连接有一个超大的、亲脂性的基团，包括至少9个非氢原子，并且具有至少两个阳离子大于阴离子的基团。本发明还涉及涉及这样的分子的治疗方法，特别是包括肽衍生物和肽类似物的肽。